Practical Considerations for Translating Mesenchymal Stromal Cell-Derived Extracellular Vesicles from Bench to Bed

Area of Science:

• Regenerative Medicine
• Biotechnology
• Orthopedics

Background:

• Mesenchymal stromal cell-derived extracellular vesicles (MSCs-EVs) are a promising cell-free therapeutic alternative for tendon and ligament injuries, avoiding risks associated with live cell transplantation.
• Current challenges include ensuring the viability, stability, and preventing erroneous differentiation of transplanted cells.

Purpose of the Study:

• To review general and tissue-specific considerations for manufacturing MSC-EVs for clinical translation.
• To discuss Good Manufacturing Practice (GMP)-compliant manufacturing, quality control, safety, and efficacy of MSC-EVs.

Main Methods:

• Review of current literature on MSC-EV manufacturing and clinical translation.
• Discussion of GMP guidelines relevant to MSC-EV production.
• Analysis of quality control parameters including cell source, culture, concentration, quantity, identity, purity, sterility, potency, reproducibility, storage, and formulation.

Main Results:

• Successful clinical translation requires robust GMP-compliant manufacturing processes for MSC-EVs.
• Key quality control parameters must be rigorously defined and monitored.
• Safety and efficacy data are crucial for regulatory approval and clinical adoption.

Conclusions:

• Standardized manufacturing and quality control protocols are essential for the reliable clinical application of MSC-EVs in tendon and ligament repair.
• Addressing manufacturing challenges will facilitate the translation of MSC-EVs into effective regenerative therapies.